2026年,美国将大麻重新分类,促进了研究和准入,同时夏威夷的医疗计划蓬勃发展,娱乐市场开始兴起,加拿大的工业尽管面临持续的挑战,但仍然在增长。 In 2026, the U.S. reclassified cannabis, boosting research and access, while Hawaii’s medical program thrives and a recreational market looms, and Canada’s industry grows despite ongoing challenges.

2026年联邦对大麻的重新分类将大麻从最严格受管制药物类别中剔除,使美国能够扩大研究、投资和病人获得治疗的机会。 A federal reclassification of cannabis in 2026 removed it from the strictest controlled substance category, enabling expanded research, investment, and patient access in the U.S. 同时,夏威夷的大麻医疗计划每月合法销售530万美元,占病人开支的86-87%,但总需求量达到每月1 700-3 200万美元,包括非法来源。 Meanwhile, Hawaii’s medical cannabis program generates $5.3 million monthly in legal sales, capturing 86–87% of patient spending, though total demand reaches $17–32 million monthly, including illicit sources. 提议的娱乐市场每月可带来5 900万至9.5亿美元的收入,税收以公共卫生和公平方案为目标。 A proposed recreational market could bring in $59–95 million monthly, with tax revenue targeted at public health and equity programs. 加拿大的大麻工业正在稳步增长,零售渠道、产品创新和国际扩张有所增加,尽管质量控制问题和监管挑战依然存在。 Canada’s cannabis industry is growing steadily, with increased retail access, product innovation, and international expansion, though quality control issues and regulatory challenges persist.